Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• Ibalizumab is a humanized IgG4 monoclonal antibody targeting CD4 receptors.
• It functions by noncompetitively blocking human immunodeficiency virus type 1 (HIV-1) entry into cells.

Purpose of the Study:

• To evaluate the efficacy and safety of ibalizumab in adults with multidrug-resistant (MDR) HIV-1 infection.
• To assess viral load reduction and clinical outcomes in patients with treatment-experienced, advanced HIV-1 disease.

Main Methods:

• A single-group, open-label, phase 3 study enrolled 40 adults with MDR HIV-1 infection.
• Patients received a loading dose of ibalizumab followed by 800 mg every 14 days, combined with an optimized background regimen.
• Viral load and CD4 counts were monitored over a 25-week study period.

Main Results:

• 83% of patients achieved a viral load decrease of at least 0.5 log10 copies/mL from baseline.
• Mean viral load reduction was 1.1 log10 copies/mL at day 14 and 1.6 log10 copies/mL at week 25.
• 43% achieved viral load <50 copies/mL and 50% <200 copies/mL by week 25. Diarrhea was the most common adverse event.

Conclusions:

• Ibalizumab demonstrated significant antiviral activity in patients with advanced MDR HIV-1 infection.
• Emergence of reduced susceptibility to ibalizumab was observed in vitro in patients with virologic failure.
• Ibalizumab represents a potential therapeutic option for patients with limited treatment alternatives.